Comparison of 26G and 30G Needles for Masseter Trigger Point Injections in Patients With Myofascial Pain Syndrome (MASS-NEEDLE)
Comparison of Two Needle Gauges (26G and 30G) for Masseter Muscle Trigger Point Injection in Myofascial Pain Syndrome: A Randomized Split-Face Controlled Trial
This randomized split-face study aims to compare the effects of 26G and 30G needles used for masseter trigger point injections with lidocaine in patients with myofascial pain syndrome. Both needle sizes are routinely used in clinical practice. Pain reduction from baseline to day 14 will be compared between the two sides of the face. Secondary outcomes include pain reduction at day 7, procedural pain, injection-site tenderness at 48 hours, bruising, and patient preference. The split-face design allows both needle sizes to be evaluated in the same patient, minimizing individual differences.
研究概览
详细说明
Both 26G and 30G needles were routinely used for masseter trigger point injection in our clinic. Comparing these gauges under otherwise standardized conditions may help clarify whether needle selection affects short-term pain reduction, procedural pain, and patient preference. A randomized split-face design permits this comparison within the same patient, reducing the influence of differences between individuals.
The primary objective of this study was to compare the within-patient reduction in palpation-evoked masseter pain between sides treated with 26G and 30G needles from baseline to day 14 following lidocaine injection. Secondary objectives were to compare pain reduction at day 7, overall procedural pain, injection-site tenderness at 48 hours, ecchymosis, and patient preference.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名：Ceylan Güzel, Dr
- 电话号码：+90 5364501650
- 邮箱：ceylan.guzel@medipol.edu.tr
学习地点
-
-
-
Istanbul、土耳其（türkiye）、34214
- Medipol Mega University Hospital
-
接触：
- Ceylan Güzel, Dr.
- 电话号码：+905364501650
- 邮箱：ceylan.guzel@medipol.edu.tr
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
Adults aged 18-65 years.
Bilateral masseter myofascial pain persisting for at least 8 weeks.
Baseline palpation-evoked pain score of ≥6 on an 11-point Numerical Rating Scale (NRS) on each side.
Presence of at least one active myofascial trigger point within a palpable taut band in each masseter muscle, reproducing the patient's familiar pain.
Diagnosis established according to the Diagnostic Criteria for Temporomandibular Disorders (DC/TMD).
No previous treatment for masseter myofascial pain.
Exclusion Criteria:
- Concomitant temporomandibular joint arthralgia.
Known allergy to local anesthetics.
Pregnancy or lactation.
Active infection, open lesion, or malignancy at the injection site.
Bleeding diathesis or use of anticoagulant or antiplatelet medications.
Inability to cooperate with study procedures.
学习计划
研究是如何设计的？
设计细节
- 主要用途：治疗
- 分配：随机化
- 介入模型：单组作业
- 屏蔽：双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的：Bilateral Masseter Trigger Point Injection 26 G
All participants received bilateral masseter trigger point injections in a single session. A 26-gauge (26G) needle was randomly assigned to one masseter muscle and a 30-gauge (30G) needle to the contralateral masseter muscle using a computer-generated randomization sequence. Each masseter received 0.3 mL of 2% lidocaine without vasoconstrictor using a standardized injection technique. The right masseter was injected first in all participants. Participants and the outcome assessor were blinded to needle-gauge allocation, whereas the injecting clinician was not blinded. |
A 26-gauge (0.45 × 13 mm) needle was used for masseter trigger point injection. A total of 0.3 mL of 2% lidocaine without vasoconstrictor was administered using a standardized injection technique. |
|
实验性的：Bilateral Masseter Trigger Point Injection 30 G
All participants received bilateral masseter trigger point injections in a single session. A 26-gauge (26G) needle was randomly assigned to one masseter muscle and a 30-gauge (30G) needle to the contralateral masseter muscle using a computer-generated randomization sequence. Each masseter received 0.3 mL of 2% lidocaine without vasoconstrictor using a standardized injection technique. The right masseter was injected first in all participants. Participants and the outcome assessor were blinded to needle-gauge allocation, whereas the injecting clinician was not blinded. |
A 30-gauge (0.45 × 13 mm) needle was used for masseter trigger point injection. A total of 0.3 mL of 2% lidocaine without vasoconstrictor was administered using a standardized injection technique. |
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Between-Needle Difference in Palpation-Evoked Masseter Pain Reduction From Baseline to Day 14
大体时间：Baseline and Day 14 (14 days after injection)
|
Palpation-evoked masseter pain was assessed separately on each side using an 11-point Numerical Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst possible pain). At baseline and day 14, pain was recorded at the most painful trigger point identified during each assessment. Pain reduction was calculated as baseline NRS minus day 14 NRS for each side. The primary outcome was the within-participant difference in pain reduction between the 30G and 26G needle interventions (30G minus 26G). Positive values indicated greater pain reduction with 30G. |
Baseline and Day 14 (14 days after injection)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Between-Needle Difference in Palpation-Evoked Masseter Pain Reduction at Day 7
大体时间：Baseline and Day 7
|
Palpation-evoked masseter pain was assessed separately on each side using an 11-point Numerical Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst possible pain). Pain reduction was calculated as baseline NRS minus day 7 NRS for each side. The within-participant difference in pain reduction between the 30G and 26G needle interventions was calculated as 30G minus 26G. Positive values indicated greater pain reduction with 30G. |
Baseline and Day 7
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Overall Procedural Pain During Masseter Trigger Point Injection
大体时间：Day 0 (within 60 seconds after each injection)
|
Overall procedural pain was assessed separately for the 26G and 30G needle interventions using an 11-point Numerical Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst possible pain). Participants rated the entire injection procedure, including skin penetration, intramuscular needle manipulation, and lidocaine administration. Pain was recorded within 60 seconds after each injection. Within-participant pain scores were compared between needle gauges. |
Day 0 (within 60 seconds after each injection)
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.